Hospitalization for musculoskeletal disorders in rheumatoid arthritis patients: A population-based study

BMC Musculoskeletal Disorders

Volumn 17, Issue 1, 2016, Pages

  Machado, Marina Amaral De Ávila ^a,b   Bernatsky, Sasha ^a   Bessette, Louis ^c   Nedjar, Hacene ^a   Rahme, Elham ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Anti TNF; DMARDs; Musculoskeletal conditions; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AUROTHIOGLUCOSE; AUROTHIOMALATE; CERTOLIZUMAB PEGOL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PROPENSITY SCORE; QUEBEC; RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; PROPORTIONAL HAZARDS MODELS; QUEBEC; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84978511605     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-016-1142-4     Document Type: Article

References (21)

1. Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559-82.
2. http://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/medicaments/liste-medicaments58.pdf. RAMQ - Régie de l'assurance maladie du Québec. List of Medications. Accessed 12 Jan 2015.
3. Simard JF, Arkema EV, Sundstrom A, Geborek P, Saxne T, Baecklund E, et al. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford). 2011;50(1):204-13.
4. Aga AB, Lie E, Uhlig T, Olsen IC, Wierod A, Kalstad S, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. Ann Rheum Dis. 2015;74(2):381-8.
5. Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis. 2008;67(1):37-42.
6. Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30(4):339-53.
7. Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford). 2012;51(12):2252-61.
8. Yasui T, Nishino J, Kadono Y, Matsui T, Nakamura K, Tanaka S, et al. Impact of biologics on the prevalence of orthopedic surgery in the National Database of Rheumatic Diseases in Japan. Mod Rheumatol. 2010;20(3):233-7.
9. Zisman D, Haddad A, Hashoul S, Laor A, Bitterman H, Rosner I, et al. Hospitalizations of patients treated with anti-tumor necrosis factor-alpha agents - a retrospective cohort analysis. J Rheumatol. 2013;40(1):16-22.
10. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512-22.
11. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48(8):999-1009.
12. Barber C, Lacaille D, Fortin PR. Systematic review of validation studies of the use of administrative data to identify serious infections. Arthritis Care Res (Hoboken). 2013;65(8):1343-57.
13. Rassen JA DMHWSS. Pharmacoepidemiology Toolbox. Boston, MA. http://www.hdpharmacoepi.org. Accessed 12 Jan 2015.
14. Schmitz N, Nitka D, Gariepy G, Malla A, Wang J, Boyer R, et al. Association between neighborhood-level deprivation and disability in a community sample of people with diabetes. Diabetes Care. 2009;32(11):1998-2004.
15. Pampalon R, Hamel D, Gamache P, Raymond G. A deprivation index for health planning in Canada. Chronic Dis Can. 2009;29(4):178-91.
16. Morgan C, McBeth J, Cordingley L, Watson K, Hyrich KL, Symmons DP, et al. The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology (Oxford). 2015;54(10):1780-91.
17. Pasma A, Schenk CV, Timman R, Busschbach JJ, van den Bemt BJ, Molenaar E, et al. Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. Arthritis Res Ther. 2015;17:281.
18. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol. 2002;29(5):1015-22.
19. Arkema EV, Neovius M, Joelsson JK, Simard JF, van Vollenhoven RF. Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study. Ann Rheum Dis. 2012;71(7):1203-6.
20. Hetland ML, Lindegaard HM, Hansen A, Podenphant J, Unkerskov J, Ringsdal VS, et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis. 2008;67(7):1023-6.
21. Kvien TK, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvag BY, et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S188-94.